FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200455429> ?p ?o ?g. }

• W4200455429 endingPage "121374" @default.
• W4200455429 startingPage "121374" @default.
• W4200455429 abstract "Monoacylglycerol lipase (MAGL) is an emerging therapeutic target for cancer. It is involved in lipid metabolism and its inhibition impairs many hallmarks of cancer including cell proliferation, migration/invasion and tumor growth. For these reasons, our group has recently developed a potent reversible MAGL inhibitor (MAGL23), which showed promising anticancer activities. Here in, to improve its pharmacological properties, a nanoformulation based on nanocrystals coated with albumin was prepared for therapeutic applications. MAGL23 was solubilized by a nanocrystallization method with Pluronic F-127 as surfactant into an organic solvent and was recovered as nanocrystals in water after solvent evaporation. Finally, the solubilized nanocrystals were stabilized by human serum albumin to create a smart delivery carrier. An in-silico prediction (lipophilicity, structure at different pH and solubility in water), as well as experimental studies (solubility), have been performed to check the chemical properties of the inhibitor and nanocrystals. The solubility in water increases from less than 0.01 mg/mL (0.0008 mg/mL, predicted) up to 0.82 mg/mL in water. The formulated inhibitor maintained its potency in ovarian and colon cancer cell lines as the free drug. Furthermore, the system was thoroughly observed at each step of the solubilization process till the final formulation stage by different spectroscopic techniques and a comparative study was performed to check the effects of Pluronic F-127 and CTAB as surfactants. The formulated system is favorable to release the drug at physiological pH conditions (at pH 7.4, after 24 h, less than 20% of compound is released). In vivo studies have shown that albumin-complexed nanocrystals increase the therapeutic window of MAGL23 along with a favorable biodistribution. As per our knowledge, we are reporting the first ever nanoformulation of a MAGL inhibitor, which is promising as a therapeutic system where the MAGL enzyme is involved, especially for cancer therapeutic applications." @default.
• W4200455429 created "2021-12-31" @default.
• W4200455429 creator A5000554056 @default.
• W4200455429 creator A5003958577 @default.
• W4200455429 creator A5015876426 @default.
• W4200455429 creator A5018528864 @default.
• W4200455429 creator A5021722929 @default.
• W4200455429 creator A5025080326 @default.
• W4200455429 creator A5029995182 @default.
• W4200455429 creator A5061448034 @default.
• W4200455429 creator A5070257255 @default.
• W4200455429 creator A5070335184 @default.
• W4200455429 creator A5072169960 @default.
• W4200455429 creator A5073450392 @default.
• W4200455429 creator A5088789126 @default.
• W4200455429 creator A5089644852 @default.
• W4200455429 date "2022-02-01" @default.
• W4200455429 modified "2023-10-16" @default.
• W4200455429 title "A Carrier Free Delivery System of a Monoacylglycerol Lipase Hydrophobic Inhibitor" @default.
• W4200455429 cites W1195955210 @default.
• W4200455429 cites W1495791112 @default.
• W4200455429 cites W1968128233 @default.
• W4200455429 cites W1985868513 @default.
• W4200455429 cites W1990796256 @default.
• W4200455429 cites W2002815709 @default.
• W4200455429 cites W2014606147 @default.
• W4200455429 cites W2014928486 @default.
• W4200455429 cites W2026930707 @default.
• W4200455429 cites W2027147390 @default.
• W4200455429 cites W2030275485 @default.
• W4200455429 cites W2036671354 @default.
• W4200455429 cites W2049340957 @default.
• W4200455429 cites W2051554315 @default.
• W4200455429 cites W2066742760 @default.
• W4200455429 cites W2083966000 @default.
• W4200455429 cites W2086660103 @default.
• W4200455429 cites W2086806820 @default.
• W4200455429 cites W2093423704 @default.
• W4200455429 cites W2094456976 @default.
• W4200455429 cites W2102260997 @default.
• W4200455429 cites W2117692326 @default.
• W4200455429 cites W2121149671 @default.
• W4200455429 cites W2127624416 @default.
• W4200455429 cites W2130136843 @default.
• W4200455429 cites W2163953252 @default.
• W4200455429 cites W2312557846 @default.
• W4200455429 cites W2318142576 @default.
• W4200455429 cites W2326853471 @default.
• W4200455429 cites W2346448021 @default.
• W4200455429 cites W2547661238 @default.
• W4200455429 cites W2560865180 @default.
• W4200455429 cites W2587553356 @default.
• W4200455429 cites W2757495183 @default.
• W4200455429 cites W2779991935 @default.
• W4200455429 cites W2799881782 @default.
• W4200455429 cites W2883498138 @default.
• W4200455429 cites W2883860383 @default.
• W4200455429 cites W2886139484 @default.
• W4200455429 cites W2886997217 @default.
• W4200455429 cites W2894511487 @default.
• W4200455429 cites W2898120862 @default.
• W4200455429 cites W2900960361 @default.
• W4200455429 cites W2911180532 @default.
• W4200455429 cites W2913644870 @default.
• W4200455429 cites W2914347692 @default.
• W4200455429 cites W2944090840 @default.
• W4200455429 cites W2948059266 @default.
• W4200455429 cites W3005169647 @default.
• W4200455429 cites W3016898417 @default.
• W4200455429 cites W3017617433 @default.
• W4200455429 cites W3021336149 @default.
• W4200455429 cites W3026471408 @default.
• W4200455429 cites W3032673817 @default.
• W4200455429 cites W3033608907 @default.
• W4200455429 cites W3083111447 @default.
• W4200455429 cites W3092888063 @default.
• W4200455429 cites W3093910350 @default.
• W4200455429 cites W3127411251 @default.
• W4200455429 cites W3184929289 @default.
• W4200455429 doi "https://doi.org/10.1016/j.ijpharm.2021.121374" @default.
• W4200455429 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34906647" @default.
• W4200455429 hasPublicationYear "2022" @default.
• W4200455429 type Work @default.
• W4200455429 citedByCount "0" @default.
• W4200455429 crossrefType "journal-article" @default.
• W4200455429 hasAuthorship W4200455429A5000554056 @default.
• W4200455429 hasAuthorship W4200455429A5003958577 @default.
• W4200455429 hasAuthorship W4200455429A5015876426 @default.
• W4200455429 hasAuthorship W4200455429A5018528864 @default.
• W4200455429 hasAuthorship W4200455429A5021722929 @default.
• W4200455429 hasAuthorship W4200455429A5025080326 @default.
• W4200455429 hasAuthorship W4200455429A5029995182 @default.
• W4200455429 hasAuthorship W4200455429A5061448034 @default.
• W4200455429 hasAuthorship W4200455429A5070257255 @default.
• W4200455429 hasAuthorship W4200455429A5070335184 @default.
• W4200455429 hasAuthorship W4200455429A5072169960 @default.
• W4200455429 hasAuthorship W4200455429A5073450392 @default.
• W4200455429 hasAuthorship W4200455429A5088789126 @default.

• next